Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind crossover dose-finding trial of HRS-9231 for CNS MRI contrast enhancement
CTR20244685Phase 2Completed
- Sponsor
- Chengdu Shengdi
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-9231 in acute neurological injury, sponsored by Chengdu Shengdi. Started Dec 2024; status: completed.
02
Drugs
HRS-9231
03
Conditions
acute neurological injury
Beyond the preview
Go deeper on CTR20244685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244685.